Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01283542 · OUTCOME

Percentage of Participants With Reduction From Baseline of Alpha Subunit ≥50% in Main and Extension Phases (FAS)

Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. · Source last updated 2019-04-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
Not reported
Time frame
Baseline up to approximately Week 96

What was measured

Alpha subunit levels were determined at a central laboratory.

Analysis population: Evaluable participants had to have 50% reduction

Groups in this outcome

Week 12

Week 12 of Main Phase

Week 24

Week 24 of Main Phase

Week 48

Week 48 of Extension Phase

Week 72

Week 72 of Extension Phase

Week 96

Week 96 of Extension Phase

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Week 1214
Week 2415
Week 4810
Week 7210
Week 966

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Week 128.3Not reportedNot reportedNot reportedNot reported
Week 2428.6Not reportedNot reportedNot reportedNot reported
Week 4812.5Not reportedNot reportedNot reportedNot reported
Week 7222.2Not reportedNot reportedNot reportedNot reported
Week 960Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        8.3
      2. group Id
        OG001
        value
        28.6
      3. group Id
        OG002
        value
        12.5
      4. group Id
        OG003
        value
        22.2
      5. group Id
        OG004
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    2. group Id
      OG001
      value
      15
    3. group Id
      OG002
      value
      10
    4. group Id
      OG003
      value
      10
    5. group Id
      OG004
      value
      6
    units
    Participants
description
Alpha subunit levels were determined at a central laboratory.
groups
  1. description
    Week 12 of Main Phase
    id
    OG000
    title
    Week 12
  2. description
    Week 24 of Main Phase
    id
    OG001
    title
    Week 24
  3. description
    Week 48 of Extension Phase
    id
    OG002
    title
    Week 48
  4. description
    Week 72 of Extension Phase
    id
    OG003
    title
    Week 72
  5. description
    Week 96 of Extension Phase
    id
    OG004
    title
    Week 96
param Type
NUMBER
population Description
Evaluable participants had to have 50% reduction
reporting Status
POSTED
time Frame
Baseline up to approximately Week 96
title
Percentage of Participants With Reduction From Baseline of Alpha Subunit ≥50% in Main and Extension Phases (FAS)
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice